Ambrosia Biosciences Secures $100 Million in Oversubscribed Series B Funding
Ambrosia Biosciences has closed a $100 million Series B funding round that saw oversubscribed demand from investors.
Boulder-based Ambrosia Biosciences has successfully closed a $100 million Series B funding round. The financing effort was oversubscribed, reflecting significant investor interest in the biotech firm’s ongoing operations and research initiatives. The company, headquartered in Colorado, intends to utilize the capital injection to accelerate its development pipeline and expand its internal research capabilities. This latest funding milestone marks a substantial step forward for Ambrosia Biosciences as it continues to advance its clinical programs. Details regarding specific lead investors or the company’s current valuation following the closing of the round were not immediately disclosed.